Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4636280 | 0.90 | ALDH1A1 (0.45) | ALBGAAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL3329390 | 0.89 | CNR1 (0.38) | PTGDR2SMN1; SMN2PKM | |
| SCHEMBL4779100 | 0.88 | TSHR (0.40) | ALBPTGDR2ALDH1A1SMN1; SMN2APEX1 | |
| SCHEMBL4635707 | 0.85 | PTGDR2 (0.43) | PTGDR2ALDH1A1LMNAKMT2ATDP1 | |
| SCHEMBL4636889 | 0.84 | MEN1 (0.35) | PTGDR2LMNAKMT2ATDP1MEN1 | |
| SCHEMBL3327642 | 0.84 | ALDH1A1 (0.45) | ALBPTGDR2GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL4636980 | 0.83 | TDP1 (0.38) | PTGDR2SMN1; SMN2LMNAKMT2ATDP1 | |
| SCHEMBL4668504 | 0.81 | P4HB (0.40) | PTGDR2ALDH1A1SMN1; SMN2HPGDLMNA | |
| SCHEMBL3329225 | 0.80 | ALDH1A1 (0.39) | ALDH1A1LMNAKMT2ATDP1MEN1 | |
| SCHEMBL4727157 | 0.79 | USP2 (0.41) | GAAALDH1A1SMN1; SMN2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| EP-1931663-A1 | IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR | Argenta Discovery Limited (GB) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007031747-A1 | IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007031747-A1 | IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | HRH4, HRH2, HRH3 | ALB 4760/4885PTGDR2 293/4885GAA 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.